During the recent session, Pfizer Inc (NYSE:PFE)’s traded shares were 3.88 million, with the beta value of the company hitting 0.61. At the last check today, the stock’s price was $26.54, reflecting an intraday loss of -0.26% or -$0.07. The 52-week high for the PFE share is $31.54, that puts it down -18.84 from that peak though still a striking 7.76% gain since the share price plummeted to a 52-week low of $24.48. The company’s market capitalization is $150.40B, and the average intraday trading volume over the past 10 days was 42.87 million shares, and the average trade volume was 42.77 million shares over the past three months.
Pfizer Inc (PFE) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.23. PFE has a Sell rating from 1 analyst(s) out of 16 analysts who have looked at this stock. 7 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.46.
Pfizer Inc (NYSE:PFE) trade information
Pfizer Inc (PFE) registered a -0.26% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.26% in intraday trading to $26.54, hitting a weekly high. The stock’s 5-day price performance is -0.07%, and it has moved by 3.83% in 30 days. Based on these gigs, the overall price performance for the year is -10.73%. The short interest in Pfizer Inc (NYSE:PFE) is 85.37 million shares and it means that shorts have 1.85 day(s) to cover.
The consensus price target of analysts on Wall Street is $32, which implies an increase of 17.06% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $30 and $36 respectively. As a result, PFE is trading at a discount of -35.64% off the target high and -13.04% off the low.
Pfizer Inc (PFE) estimates and forecasts
Statistics show that Pfizer Inc has outperformed its competitors in share price, compared to the industry in which it operates. Pfizer Inc (PFE) shares have gone down -5.38% during the last six months, with a year-to-date growth rate more than the industry average at 59.78% against 8.20. In the rating firms’ projections, revenue will increase 7.57% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 17.13B as predicted by 17 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 14.36B by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 14.25B and 14.88B respectively. In this case, analysts expect current quarter sales to grow by 20.25% and then drop by -3.48% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -27.43%. While earnings are projected to return 58.79% in 2025, the next five years will return 7.55% per annum.
PFE Dividends
Pfizer Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Pfizer Inc is 1.68, with the dividend yield indicating at 6.33 percent, continuing the trend of increasing dividends in recent years. The average dividend yield of the company for the last 5 years is 4.32%.
Pfizer Inc (NYSE:PFE)’s Major holders
Pfizer Inc insiders own 0.05% of total outstanding shares while institutional holders control 67.79%, with the float percentage being 67.82%. VANGUARD GROUP INC is the largest shareholder of the company, while 3645.0 institutions own stock in it. As of 2024-06-30, the company held over 511.4 million shares (or 9.0402% of all shares), a total value of $14.31 billion in shares.
The next largest institutional holding, with 424.38 million shares, is of BLACKROCK INC.’s that is approximately 7.5018% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $11.87 billion.
